230 related articles for article (PubMed ID: 19670961)
1. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
3. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
6. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
9. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
10. [Syk inhibitors].
Kimura Y; Chihara K; Takeuchi K; Sada K
Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
13. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
14. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
15. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
[TBL] [Abstract][Full Text] [Related]
16. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
[TBL] [Abstract][Full Text] [Related]
17. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.
Hall J; Aulabaugh A; Rajamohan F; Liu S; Kaila N; Wan ZK; Ryan M; Magyar R; Qiu X
J Biol Chem; 2012 Mar; 287(10):7717-27. PubMed ID: 22219190
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
20. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
